• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

拓扑异构酶突变和外排在脆弱拟杆菌临床分离株及实验室突变株氟喹诺酮耐药中的作用

Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants.

作者信息

Ricci Vito, Peterson Marnie L, Rotschafer John C, Wexler Hannah, Piddock Laura J V

机构信息

Antimicrobial Agents Research Group, Division of Immunity and Infection, University of Birmingham, Birmingham B15 2TT, United Kingdom.

出版信息

Antimicrob Agents Chemother. 2004 Apr;48(4):1344-6. doi: 10.1128/AAC.48.4.1344-1346.2004.

DOI:10.1128/AAC.48.4.1344-1346.2004
PMID:15047539
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC375253/
Abstract

Twelve laboratory mutants and 32 ciprofloxacin-resistant isolates of Bacteroides fragilis were examined for the mechanism(s) of fluoroquinolone resistance. Five mutants had mutations in gyrA. One mutant and two clinical isolates contained a mutation in gyrB. Eight mutants and five clinical isolates accumulated significantly less ciprofloxacin than did wild-type isolates; the mutants and clinical isolates were restored to wild-type characteristics when carbonyl cyanide m-chlorophenylhydrazone was used.

摘要

对12株实验室突变株和32株脆弱拟杆菌环丙沙星耐药菌株进行了氟喹诺酮耐药机制研究。5株突变株gyrA发生突变。1株突变株和2株临床分离株gyrB发生突变。8株突变株和5株临床分离株积累的环丙沙星明显少于野生型菌株；当使用羰基氰化物间氯苯腙时，这些突变株和临床分离株恢复为野生型特征。

相似文献

1
Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants.拓扑异构酶突变和外排在脆弱拟杆菌临床分离株及实验室突变株氟喹诺酮耐药中的作用
Antimicrob Agents Chemother. 2004 Apr;48(4):1344-6. doi: 10.1128/AAC.48.4.1344-1346.2004.
2
Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.野生型、外排阳性或含有ParC或GyrA突变的肺炎链球菌分离株的单步氟喹诺酮耐药突变体的突变预防浓度。
Antimicrob Agents Chemother. 2004 Oct;48(10):3954-8. doi: 10.1128/AAC.48.10.3954-3958.2004.
3
Plasmid-mediated complementation of gyrA and gyrB in fluoroquinolone-resistant Bacteroides fragilis.氟喹诺酮耐药脆弱拟杆菌中gyrA和gyrB的质粒介导互补作用
J Antimicrob Chemother. 2003 Sep;52(3):481-4. doi: 10.1093/jac/dkg368. Epub 2003 Aug 13.
4
Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.不同氟喹诺酮类药物对体外筛选出的携带拓扑异构酶突变的炭疽芽孢杆菌突变株的活性。
Antimicrob Agents Chemother. 2004 Aug;48(8):3024-7. doi: 10.1128/AAC.48.8.3024-3027.2004.
5
Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin.gyrA基因突变在脆弱拟杆菌临床分离株及体外突变株对新型氟喹诺酮类药物曲伐沙星耐药性中的作用。
Antimicrob Agents Chemother. 2000 Jul;44(7):1842-5. doi: 10.1128/AAC.44.7.1842-1845.2000.
6
Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.铜绿假单胞菌环丙沙星耐药临床分离株中拓扑异构酶II的GyrA和GyrB亚基以及拓扑异构酶IV的ParC和ParE亚基的改变。
Int J Antimicrob Agents. 2005 Apr;25(4):290-5. doi: 10.1016/j.ijantimicag.2004.11.012.
7
Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong.香港耐氟喹诺酮沙门氏菌拓扑异构酶基因的突变
Antimicrob Agents Chemother. 2003 Nov;47(11):3567-73. doi: 10.1128/AAC.47.11.3567-3573.2003.
8
DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis.奇异变形杆菌中与氟喹诺酮耐药性相关的DNA促旋酶和拓扑异构酶IV突变
Antimicrob Agents Chemother. 2002 Aug;46(8):2582-7. doi: 10.1128/AAC.46.8.2582-2587.2002.
9
Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.意大利出现的对氟喹诺酮类药物敏感性降低的临床肺炎链球菌分离株的分子特征分析
Microb Drug Resist. 2004 Fall;10(3):209-17. doi: 10.1089/mdr.2004.10.209.
10
The roles of mutations in gyrA, parC, and ompK35 in fluoroquinolone resistance in Klebsiella pneumoniae.肺炎克雷伯菌中gyrA、parC和ompK35基因突变在氟喹诺酮耐药性中的作用。
Microb Drug Resist. 2003 Fall;9(3):265-71. doi: 10.1089/107662903322286472.

引用本文的文献

1
Antibiotic Resistance and Mechanisms of Pathogenic Bacteria in Tubo-Ovarian Abscess.输卵管卵巢脓肿中病原菌的耐药性及机制
Front Cell Infect Microbiol. 2022 Jul 27;12:958210. doi: 10.3389/fcimb.2022.958210. eCollection 2022.
2
Inhibitory Concentrations of Ciprofloxacin Induce an Adaptive Response Promoting the Intracellular Survival of Salmonella enterica Serovar Typhimurium.环丙沙星的抑制浓度诱导沙门氏菌 Typhimurium 细胞内生存的适应性反应。
mBio. 2021 Jun 29;12(3):e0109321. doi: 10.1128/mBio.01093-21. Epub 2021 Jun 22.
3
Alarmingly High Segregation Frequencies of Quinolone Resistance Alleles within Human and Animal Microbiomes Are Not Explained by Direct Clinical Antibiotic Exposure.令人担忧的是，人类和动物微生物群中喹诺酮抗性等位基因的高分离频率无法通过直接临床抗生素暴露来解释。
Genome Biol Evol. 2015 May 26;7(6):1743-57. doi: 10.1093/gbe/evv102.
4
Anaerobic infections: update on treatment considerations.厌氧感染：治疗注意事项的最新进展。
Drugs. 2010 May 7;70(7):841-58. doi: 10.2165/11534490-000000000-00000.
5
Efflux-mediated drug resistance in bacteria: an update.细菌中由外排介导的耐药性：最新进展
Drugs. 2009 Aug 20;69(12):1555-623. doi: 10.2165/11317030-000000000-00000.
6
Bacteroides: the good, the bad, and the nitty-gritty.拟杆菌：有益、有害与关键细节
Clin Microbiol Rev. 2007 Oct;20(4):593-621. doi: 10.1128/CMR.00008-07.
7
Efflux pump overexpression in multiple-antibiotic-resistant mutants of Bacteroides fragilis.脆弱拟杆菌多重耐药突变体中外排泵的过表达
Antimicrob Agents Chemother. 2006 Sep;50(9):3150-3. doi: 10.1128/AAC.00141-06.
8
A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.大肠杆菌DNA促旋酶中一种赋予喹诺酮抗性的突变导致对靶向真核拓扑异构酶II的药物敏感。
Antimicrob Agents Chemother. 2004 Dec;48(12):4495-504. doi: 10.1128/AAC.48.12.4495-4504.2004.
9
Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents.新型氟喹诺酮类药物WCK 771与其他九种药物的抗厌氧活性比较。
Antimicrob Agents Chemother. 2004 Aug;48(8):3188-92. doi: 10.1128/AAC.48.8.3188-3192.2004.

本文引用的文献

1
Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones.脆弱拟杆菌对加替沙星的蓄积与五种氟喹诺酮类药物的比较。
J Antimicrob Chemother. 2003 Oct;52(4):605-9. doi: 10.1093/jac/dkg418. Epub 2003 Sep 1.
2
Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones.与其他五种氟喹诺酮类药物相比，耐莫西沙星金黄色葡萄球菌的选择
J Antimicrob Chemother. 2003 Jun;51(6):1403-7. doi: 10.1093/jac/dkg241. Epub 2003 Apr 25.
3
Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.在体外药效学模型中曲伐沙星和左氧氟沙星对脆弱拟杆菌的药效学研究
Antimicrob Agents Chemother. 2002 Jan;46(1):203-10. doi: 10.1128/AAC.46.1.203-210.2002.
4
A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron.一个MATE家族多药外排转运蛋白将氟喹诺酮类药物泵出多形拟杆菌。
Antimicrob Agents Chemother. 2001 Dec;45(12):3341-6. doi: 10.1128/AAC.45.12.3341-3346.2001.
5
Determination of minimum inhibitory concentrations.最低抑菌浓度的测定
J Antimicrob Chemother. 2001 Jul;48 Suppl 1:5-16. doi: 10.1093/jac/48.suppl_1.5.
6
Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone.
Infection. 2000 Sep;28(5):272-7. doi: 10.1007/s150100070018.
7
Accumulation of norfloxacin by Bacteroides fragilis.脆弱拟杆菌对诺氟沙星的蓄积
Antimicrob Agents Chemother. 2000 Sep;44(9):2361-6. doi: 10.1128/AAC.44.9.2361-2366.2000.
8
Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin.gyrA基因突变在脆弱拟杆菌临床分离株及体外突变株对新型氟喹诺酮类药物曲伐沙星耐药性中的作用。
Antimicrob Agents Chemother. 2000 Jul;44(7):1842-5. doi: 10.1128/AAC.44.7.1842-1845.2000.
9
Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase.脆弱拟杆菌编码DNA促旋酶的gyrA和gyrB基因的分子克隆。
Antimicrob Agents Chemother. 1999 Oct;43(10):2423-9. doi: 10.1128/AAC.43.10.2423.
10
Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.司帕沙星暴露后脆弱拟杆菌对氟喹诺酮类药物的耐药性
Antimicrob Agents Chemother. 1999 Sep;43(9):2251-5. doi: 10.1128/AAC.43.9.2251.